Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuated dose rituximab with chemotherapy in chronic lymphocytic leukaemia
2009-010998-20Phase 4Unknown
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Complete response rate by IWCLL criteria. Status: unknown.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-010998-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010998-20.